| Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells. | colorectal, |
| Associations between PIK3CA expression and clinicopathological variables, molecular classes, and patients_ outcome were investigated. PIK3CA is an oncogenic biomarker associated with poor prognosis in breast cancer. | breast, |
| PIK3CA mutations mostly began to develop at the stage from the DIN1B to the carcinoma in situ (DCIS), which is a late event of breast oncogenesis. | breast, |
| Activation of the PI3K-Akt pathway by human T cell leukemia virus type 1 (HTLV-1) oncoprotein Tax increases Bcl3 expression, which is associated with enhanced growth of HTLV-1-infected T cells. | leukemia, |
| Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations. | skin, |
| The PIK3CA H1047R oncogene targets a multipotent progenitor cell and, furthermore, show that this model recapitulates features of human breast tumors with PIK3CA H1047R. | breast, |
| Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma. | oral |
| data confirm that PIK3CA is important to oral squamous cell carcinoma (OSCC) tumorigenesis and can contribute to oncogene activation of the PIK3CA/AKT pathway in OSCC | oral |
| Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. | breast, |
| Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. | lung, |
| Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas. | pituitary, |
| Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers. | endometrial, |
| Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells. | breast, |
| Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. | pancreatic, |
| Data show that somatic cell knockin of both KRAS G12V and oncogenic PIK3CA mutations in human breast epithelial cells results in cooperative activation of the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways. | breast, |
| Genetic deregulation of the PIK3CA oncogene in oral cancer. | oral |
| the review provides a complete picture of the PIK3CA oncogene and its deregulation in oral cancer (Review) | oral |
| Uterine serous carcinoma cell lines with oncogenic PIK3CA mutations were significantly more sensitive to GDC-0980 exposure. | uterine, |
| Phosphatidylinositol 3-kinase (PI3KCA) oncogene mutation analysis and gene expression profiling in primary breast cancer patients. | breast, |
| Data indicate that oncogenic activation of the phosphoinositide 3-kinase (PI3K) pathway involving phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA) gene mutations can contribute to the progression of mucin-producing neoplasms | neoplasm, |